n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
SALT LAKE CITY, Oct. 16, 2023 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique and proprietary platform for the progression of molecular diagnostic testing, announced that the Company will have a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa, from October 17-19, 2023.
The convention is described as the largest gathering of healthcare companies, technologies and products in the sub-Saharan region, and targets an audience of professionals from the South African Development Community region and around the world, adding distributors, government representatives and laboratory executives. and purchasing/procurement managers, who come to meet with world-class suppliers and manufacturers.
Co-Dx believes the display will provide valuable insights into the markets that are expected to play a role in the company’s long-term as it prepares to launch its upcoming Co-Dx PCR Home™ platform.
In addition to a COVID-19 test, which is lately under clinical evaluation on the platform for submission to the FDA, Co-Dx has several other infectious disease tests in development stages. One such test is for tuberculosis (TB), a disease for which the World Health Organization estimates that 25% of new international cases and deaths occur in the African region. Nigeria and South Africa are two of the seven countries estimated to account for more than two-thirds of the world’s TB cases. .
Co-Dx recently announced that it won money from the Bill Foundation.
More facts about the convention can be found here. Attendees interested in learning more about the corporate are invited to booth No. 2. C13.
The Co-Dx PCR Home platform is subject to FDA review and is not available for sale.
About Co-Diagnostics, Inc. :Co-Diagnostics, Inc. , a Utah company, is a molecular diagnostics company that develops, manufactures, and markets next-generation diagnostic technologies. The company’s technologies are used for engineered tests that employ the detection and/or investigation of nucleic acid molecules (DNA or RNA). The company is also using its proprietary generation to design rapid assays for its Co-Dx PCR Home™ platform and to locate genetic markers for use in non-infectious disease programs.
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of threats and uncertainties. Forward-looking statements may be referred to by words such as “believes,” “expects,” “estimates,” “intends,” “possibly,” “plans,” “will” and similar expressions, or by the negative form of such words. . These forward-looking statements are based on facts and situations as they exist at the time such statements are made and on predictions of events and situations in the long term. Forward-looking statements contained in this release include statements related to our confidence that our new platform will assist global efforts to prevent the spread of tuberculosis and HPV and our confidence that our new platform has the potential to particularly facilitate access to diagnoses and reduce health care costs. Actual effects could differ materially from those contemplated or expected by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on forward-looking statements. There can be no assurance that any of the expected effects will occur in a timely manner or at all due to certain threats and uncertainties, a discussion of which can be found in our disclosure on risk points in our annual report at the Form 10-K. , filed with the Securities and Exchange Commission (SEC) on March 16, 2023, as well as in our other SEC filings. The Company undertakes no legal responsibility to update any forward-looking statements relating to the matters discussed in this press release, unless required by applicable securities laws.
Consult the content to download the multimedia: https://www. prnewswire. com/news-releases/co-diagnostics-inc-to-host-booth-at-medlab-africa-2023-in-johannesburg-south-africa -301957262Matrixhtml
SOURCE Co-diagnosis